chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Red rash on arm after receiving vaccine; A spontaneous report was received from a consumer concerning a 66-years old male patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced the event red rash on arm after receiving vaccine/rash.   The patient's medical history was not provided. No relevant concomitant product use was reported.  On 20 Jan 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (lot/batch: unknown) in the left arm for prophylaxis of COVID-19 infection. The route of administration was unknown.    On an unknown date, the patient experienced rash on arm after receiving vaccine.  No treatment details were provided.  Action taken with mRNA-1273 in response to the events was unknown.  The outcome of the event rash on arm after receiving vaccine was unknown.
I had soreness/achy feeling in my arm after receiving the vaccine. I started having symptoms of a cold or flu on 07/08/22.  I felt achy all over and I had a runny nose. My symptoms got worse after a couple  of days so  I had a PCR test done at an urgent care center which confirmed the positive COVID 19  on 07/10/22. I went home and later that day/night I went into respiratory distress and had to go to the emergency room.  They kept me for observation and gave me breathing treatments and medication. As of today I continue to feel bad and I have no energy. I have been to my doctor and they tell me it's just going to take longer to recover.  I also tested positive for COVID 19 in January 2022.
mom reports 6wk p/vax pt devel arthritic type pain in joints,  low grade fever & achy all over;also swelling in joint of fingers;@ one point pt needed help getting up off couch;MD stated arthritis may be from vax or another type infect;
3-23-21 4:16PM PT STATES 'EYES FEEL WEIRD, HARD TO REFOCUS QUICKLY AND EARS RINGING'. PT PLACED IN CHAIR. A/O, PINK, W/D, RESP REG WITH EASE. PERLA. NO NEURO DEFICIT. GOOD MOTOR/SENSORY NOTED. COMFORT GIVEN. 4:17PM STATES SHE 'FEELS BETTER NOW'. 4:25PM AMBULATORY TO EXIT - GAIT BRISK AND STEADY. NO DISTRESS NOTED. 3-24-21 9:45AM PT STATES SHE 'FEELS MUCH BETTER'.
Pityriasis rosea; This is a spontaneous report from a non-contactable consumer (patient). A 17-year-old female patient received second dose of BNT162B2 on 21May2021 05:00 PM (at age of 17-year-old) at single dose on left arm for Covid-19 immunization. Medical history and concomitant medications were not reported. Historical vaccine included first dose of BNT162B2 on 30Apr2021 05:00 PM (at age of 17-year-old) for Covid-19 immunization. No other vaccines within 4 weeks prior to the COVID vaccine. Patient experienced Pityriasis rosea on 23May2021. Patient received Mometasone cream as treatment. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. Patient had Nasal Swab on 04Jun2021 with result of negative. The outcome of the event was unknown. The event reported serious.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Pt developed cellulitis to left arm injection site.  Area was red, hot and painful to touch.  Admitted to hospital and given IV antibiotics. The discharge summary received on 2/10/04 states swelling and volume depleted. The medical record received on 2/10/04 states difficulty moving, malaise, nausea, vomiting, and loose stools.
After first Moderna vaccine had several migraines with the Z's but they were unusual. Usually I have a path of Z's going left to right and then at my age I had  a very slight headache. These looked different with broken up lights. and I woke up with them.Then on Feb 24  :1t 1:15 I had my second. The next morning I woke up with a hazy eyesight but I thought it might be a migraine. I somehow knew it wasn't but didn't go to a doctor. The next morning definitely knew.  Saw 2 doctors one in emergency situation he placed me on steroids but I had lost part of my eye sight.
On 4/10 I started feeling tired with muscle aches.  A few days later my skin started to hurt.  Clothing was uncomfortable when it moved across my skin. Those symptoms lasted about a week. Then as they started to lessen I had some back pain (Sciatic) and a sore throat.  Also the muscles behind my eyes were slightly painful and bright lights were uncomfortable.  Then about  4/21 most of the symptoms reduced and I was feeling close to normal.  Then on 4/22 I was brushing my teeth and noticed that I couldn?t spit water like normal.  I called my GP doc and she recommended I head to the ER.   After thinking about it I also remember on 4/21 while drinking something I had some water squirt out of my lips.  At the time I thought I was just being clumsy but in hindsight the muscle weakness in my face started on 4/20.   I checked into the ER on 4/22.  When I checked into the hospital my facial weakness was very difficult to notice.  By the evening of 4/22 it was noticeable if I tried to ?show my teeth? or make a big smile. By the morning of 4/23 it was very noticeable.  The morning of 4/24 I couldn?t move my lips, nose or eyebrows.  My tongue, jaw and throat were not impacted at all.   I was started on plasmapheresis on  4/24. I had another treatment on 4/25. I noticed facial weakness was very slightly recovering the evening of 4/25.  By 4/27 my facial weakness is still healing with noticeable improvement day to day.
Patient attributes left upper arm weakness to the second dose of his  COVID-19 vaccine administration on 2 16/21. Patient visited emergency  department (ED) on 4/5/21 complaining of weakness in left upper extremity  (LUE); unable to adduct or flex left shoulder beyond 15 degrees. ED noted that he  has equal grip strength bilaterally and able to raise shoulders equally. Patient  reports weakness is affecting his ADLs (including driving). Neurology assessed  patient on 5/17/21 for LUE weakness. Reportedly, he had no issues with the first  or second doses of the Pfizer COVID-19 mRNA vaccine except LUE weakness.  Some dull, constant pain of mild severity noted in left shoulder. Neurology also  noted his left shoulder active range of motion is only 15 degrees of abduction but  has full passive ROM. Strength was decreased in L shoulder abduction and flexion  as well as flexion at the elbow. There was moderate left biceps atrophy as  compared to right. L biceps reflex was absent. There is bilateral hand intrinsic  muscle atrophy of the ulnar muscles and swan-neck changes deformities  particularly of digits 4 and 5. There is no loss of sensation in the C5-6 dermatomal  distributions. Sensory exam shows decreased vibration and proprioception at the  toes as well as reflexes were diminished or absent on the left upper extremity.  MRI of brain did show some degenerative changes around C3. Concern for C5 6  radiculopathy; however difficult for unifying diagnosis per neurology.
23SEP97 pt sx began w/sparse itchiness on various parts of body;24SEP inc hyper & agitated feeling which worsened evening of 24SEP;awoke that noc w/hives & swelling, aches in rt elbow;c/o feeling shaky;
This is a 40y.o. male significant for post-cholecystectomy syndrome, malabsorption, migraines, GERD, androgenic alopecia, and tachycardia who presents with intractable n/v since yesterday. He was found to be COVID+ Monday night. He does have issues with chronic n/v. He denies ETOH of cannabis use. Patient was seen by GI, and cleared for DC. Also seen by ID, no COVID txt needed at this time. Patient feels better after IVF. No further work up per GI. Discharged in a stable condition.
This spontaneous report was received from Registered Nurse regarding to a 12 month old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 27-MAY-2016, the patient was vaccinated with improperly stored VARIVAX (lot # L004649, expiry date 11-FEB-2017) (therapy type digital data logger) dosage regimen unknown. It was reported that the vaccine was exposed to a temperature excursion of 23 degree Celsius for a time frame of 1 hour and 29 minutes and the temperature was back in range. It was reported that the vaccine was not subjected to previous temperature excursion. Product quality complaint (PQC) was not filed. This is one of the several reports received from the same reporter. Additional information has been requested.
A few hours post vax, pt developed hives on soft tissue of eyes. Pt experienced severe swelling.
Developed a large local reaction of erythema & edema (17 X 12cm) at site of MENACTRA vaccine injection. Size increasing with time (+) pruritis. No resp symptoms. Treated with diphenhydramine, ice & prednisone. Also developed rash on upper torso. Symptoms resolved after 1 week. MENACTRA given 12-13-10.
Thursday 8/26/2021  I started to experience flashes of bright white light on the left side of my vision in my left eye. The following day I began to experience increased flashes of light and numerous floaters affecting my vision causing to to be blurry
The vial was stored in the refrigerator on 04-JUN-2023 after expiration date 11-MAY-2023; No adverse event; Dose administered to patient on 5-JUN-2023 from vials of the Moderna COVID-19 bivalent vaccine that was expired on 11-MAY-2023; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered to patient on 5-JUN-2023 from vials of the Moderna COVID-19 bivalent vaccine that was expired on 11-MAY-2023), PRODUCT STORAGE ERROR (The vial was stored in the refrigerator on 04-JUN-2023 after expiration date 11-MAY-2023) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7143C) for COVID-19 prophylaxis.     No Medical History information was reported.    On 05-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 05-Jun-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered to patient on 5-JUN-2023 from vials of the Moderna COVID-19 bivalent vaccine that was expired on 11-MAY-2023). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was stored in the refrigerator on 04-JUN-2023 after expiration date 11-MAY-2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered to patient on 5-JUN-2023 from vials of the Moderna COVID-19 bivalent vaccine that was expired on 11-MAY-2023), PRODUCT STORAGE ERROR (The vial was stored in the refrigerator on 04-JUN-2023 after expiration date 11-MAY-2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Dose administered to patient on 5-JUN-2023 from vials of the Moderna COVID-19 bivalent vaccine that was expired on 11-MAY-2023) and PRODUCT STORAGE ERROR (The vial was stored in the refrigerator on 04-JUN-2023 after expiration date 11-MAY-2023).    No concomitant medication was reported.  Suspect product dosage text was reported as unknown. It was reported that no adverse reactions have been reported by any patients. The vial was initially stored in the refrigerator on 4-JUN-2023 and did not underwent any temperature excursions. No treatment medication was reported. This case is reported for patient 39 out of 50 patients   This case was linked to US-MODERNATX, INC.-MOD-2023-735331 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-735331:Master case
vaccine being unavailable; unable to get the second dose; No adverse event; This spontaneous case was reported by a patient and describes the occurrence of PRODUCT AVAILABILITY ISSUE (vaccine being unavailable), PRODUCT ADMINISTRATION INTERRUPTED (unable to get the second dose) and NO ADVERSE EVENT (No adverse event) in a 36-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 047C22A) for COVID-19 prophylaxis.     Patient had no allergy or disease. Patient did not you receive any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 27-Feb-2023, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT AVAILABILITY ISSUE (vaccine being unavailable), PRODUCT ADMINISTRATION INTERRUPTED (unable to get the second dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT AVAILABILITY ISSUE (vaccine being unavailable), PRODUCT ADMINISTRATION INTERRUPTED (unable to get the second dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.   For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT AVAILABILITY ISSUE (vaccine being unavailable) and PRODUCT ADMINISTRATION INTERRUPTED (unable to get the second dose).    No concomitant medication were reported.  Patient was unable to get the second dose due to the vaccine being unavailable. No treatment information was provided by the reporter.
Information has been received from a physician concerning a male patient who on an unknown date was vaccinated with the second dose of VARIVAX (Merck) (lot# 665417/1129Y). On an unknown date, the patient came down with chicken pox. The patient also mentioned that he got the vaccine from a fellow physician and transported it from one floor to another and was not sure on the storage of the vaccine at a previous location. It was unknown if the patient sought medical attention. At the time of reporting, the patient's status was unknown. The patient's brother also experienced chickenpox after vaccination with the same lot# 665417/1129Y. The patient's brother's information has been captured in WAES# 1001USA01876. Additional information has been requested.
Itchy rash on her leg and on her arm; This spontaneous case was reported by a consumer and describes the occurrence of RASH PRURITIC (Itchy rash on her leg and on her arm) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039A21A) for COVID-19 vaccination.     Concomitant products included ESCITALOPRAM OXALATE (LEXAPRO) for an unknown indication.    On 29-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced RASH PRURITIC (Itchy rash on her leg and on her arm). The patient was treated with CETIRIZINE ongoing since an unknown date for Symptomatic treatment, at an unspecified dose and frequency. At the time of the report, RASH PRURITIC (Itchy rash on her leg and on her arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.        .
This patient had vaccination, he walked approximately 20 and passed out. He became alert almost immediately. The mother said he had not eaten, the patient was given sprite and told to lye down 5-10 minutes. The patient appeared fine and left health unit.
No additional AEs; Caller reported ROTATEQ administered after temperature excursion.; This spontaneous report has been received from a medical assistant, concerning a patient of unknown age and gender. No information was provided regarding the patient's pertinent medical history, concurrent conditions, concomitant medications, previous drug reactions or allergies.  On an unknown date, the Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) lot number 1742431 underwent a temperature excursion of 9.2 C for a time frame of 36 minutes, no previous temperature excursion were experienced (product storage error).   On 22-MAR-2022, the patient was vaccinated with the improperly stored Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) administered at a dose of 2 milliliters (mL) per oral (PO)(lot number reported and validated as 1742431, expiration date reported and stablished as 31-JAN-2023) (strength and vaccination scheme were not provided) (product storage error). No other adverse events (AE) reported (no adverse event).
Client C/O dizziness. Writer called on NP, Site Lead and EMS. Client stood up and walked into the clinical setting, escorted by EMS and writer. Staff lowered client to the floor on a mat, inside of the clinical setting. Ortho B/P's along with O2 saturation and pulse obtained. Initial V/S @1132 noted as 107/68, 96% O2 on RA and P 83. During assessment, client and her mother verbally explained that client has a HX of anxiety during blood draws. Clients 1142 V/S completed in a laying position, noted as 105/65, P 85 and O2 98%; @1152 V/S completed in a sitting position as 101/67, O2 100% on RA, P 85; V/S completed @ 1203 in a standing position noted as B/P 103/71, P 89 and O2 100% on RA.  Client monitored for an additional 15 minutes in the outside monitoring area before being discharged by NP.
Dose next day menstural cycle start; Fever; Itching; Rash; Swollen mouth, palms and legs; Swollen mouth, palms and legs; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 34 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 23Jan2022 11:00 (Lot number: FJ1614) at the age of 34 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: FJ1614, Location of injection: Arm Left, Vaccine Administration Time: 02:00 PM), administration date: 02Jan2022, when the patient was 34 years old, for COVID-19 Immunization. The following information was reported: MOUTH SWELLING (non-serious), PERIPHERAL SWELLING (non-serious) all with onset 23Jan2022 12:00, outcome "recovering" and all described as "Swollen mouth, palms and legs"; MENSTRUAL DISORDER (non-serious) with onset 24Jan2022, outcome "recovering", described as "Dose next day menstural cycle start"; PYREXIA (non-serious) with onset 24Jan2022, outcome "recovering", described as "Fever"; PRURITUS (non-serious) with onset 23Jan2022 12:00, outcome "recovering", described as "Itching"; RASH (non-serious) with onset 23Jan2022 12:00, outcome "recovering", described as "Rash". The events "swollen mouth, palms and legs", "swollen mouth, palms and legs", "dose next day menstural cycle start", "fever", "itching" and "rash" were evaluated at the physician office visit. Therapeutic measures were taken as a result of mouth swelling, peripheral swelling, menstrual disorder, pyrexia, pruritus, rash.  Additional Information: No other vaccines were received within 4 weeks prior to the COVID vaccine. Prior to vaccination, patient was not diagnosed with COVID-19.Since the vaccination, patient been not tested for COVID-19. No other medications were received within 2 weeks of vaccination. Patient was given Benadryl as treatment for adverse event. Device date was 03Feb2022.  No follow-up attempts are possible. No further information is expected.
Experienced loss of appetite.  Weakness.  Started with pelvic soreness and pain increased where patient couldn't walk.  Admitted to Emergency Room and diagnosed with Acute Lymphoblastic leukemia.
I had a sore throat and went into a cold, I did test and to was negative for COVID-19. I had a really bad cough, It has went away today.
Swollen/ tender collar bone and area. Neck pain all on right side along with knot that maybe lymph node swelling.
Passed out; Blood pressure dropped; Neck ache; Body ache; Dizziness; Nausea; Vomiting; Severe chills; Injection site swelling; A spontaneous report was received from a consumer, concerning a 86-year-old, female patient, who received Moderna's COVID-19 vaccine and experienced passed out, blood pressure dropped, neck, body ache, dizziness, nausea, vomiting, severe chills and injection site swelling.  The patient's medical history was not provided. Concomitant product use was not provided.  On 05 Feb 2021 at 10:00 am, prior to the onset of the events, patient received their first of two planned doses of mRNA-1273 (Lot number: unknown) intramuscularly for prophylaxis of COVID-19 infection.  On 05 Feb 2021, initially patient had injection site swelling. Then 22 hours later on 06 Feb 2021, she passed out, her blood pressure dropped, had nausea, vomiting, severe chills, neck and body ache, and dizziness. No treatment information was provided.  Action taken with mRNA-1273 in response to the events were not reported.  The outcome of the events, passed out, blood pressure dropped, neck, body ache, dizziness, nausea, vomiting, severe chills and injection site swelling were unknown at the time of this report.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
pt had no problem following vax until 26OCT92 devel t105 w/listlessness; dx in EER as URI-given Amoxicillen & cough prep;
3 days after receiving yellow fever vaccine "in his triceps", had significant pain in muscles of arm, back, scapula, neck and chest.
Patient received 2 meningitis vaccines at a vaccine drive at her high school offered by the local health dept on 8/31/23. Over the course of the next day, she developed severe pain localized to her left upper deltoid where the vaccines were reportedly administered. She has no erythema/ swelling/ induration around the site. She has no findings of hematoma or other local injury. She is unable to abduct her left shoulder more than 30 degrees due to the sharp pain. Pain does not radiate. She is being managed with supportive care. Naproxen 220mg/tab, take 2 tabs q 12 hours for 4 days. Also using Salonpas lidocaine patches once daily as needed for 3 days to the site. She was asked to do slow range of motion exercises starting in the next 2 days to improve coruscation and prevent reconditioning.
Patient experience soreness in the arm after vaccine adminstration. Even after 10 days patient still had soreness in the arm and trouble lifting her arm.
Initial report was received 15 October 2010 from a health care professional which involved a cluster of three patients (one male and two female). This case captures one male patient. The other two patients (both female) have been captured in case number 2010-05986. A male patient had received an injection of FLUZONE, lot number U3720AA (routes and sites unknown) on 13 October 2010 and two days later on 15 October 2010, he experienced shortness of breath (SOB), upper respiratory infection (URI), "pruritus", swelling of eyes, irritable throat and lymphadenopathy. Corrective treatment consisted of steroids. Concomitant medications and relevant laboratory and diagnostic testing were unknown at the time of the report. Outcome was unknown. Documents held by sender: None.
This spontaneous report as received from a pharmacy technician refers to a multiple anonymous patients of unknown age. On an unknown date the patients were vaccinated with RECOMBIVAX HB (dose and route of administration were not provided). On an unknown date the patients have been administered RECOMBIVAX HB post supported excursion. No adverse effects noted by any patients. This is one of several reports from the same source. Additional information has been requested.
muscle Twiting and  Fasciculation started after a month in few places and then spread all over body.  This still persisit.  Note - this is also happening to my husband who took same vaccine , same day and same place
local rxn area w/redness & soreness approx 2in induration in diameter;